REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation (RESET-VT)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Prague, Czechia, 15030
- Homolka Hospital
-
-
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ≥ 18 years of age
- Structural heart disease (post-MI, dilated cardiomyopathy, sarcoid myopathy, hypertrophic cardiomyopathy, chagas-related cardiomyopathy, etc.)
- Planned for catheter-based ablation of VT
- All patients will have an existing ICD
- Accessibility of renal vasculature (determined by renal angiography)
- Ability to understand the requirements of the study
- Willingness to adhere to study restrictions and comply with all post- procedural follow-up requirements
Exclusion Criteria:
- MI or CVA within 30 days
- Coronary Artery Bypass Graft (CABG) within 30 days of this procedure
- Known renovascular abnormalities that would preclude RSDN (eg, renal artery stenosis)
- GFR <30 ml/min (unless receiving dialysis)
- Life expectancy <1 year for any medical condition
- Any condition resulting in a contraindication to anticoagulation (e.g. GI bleeding)
- Inability to give informed consent
- Known pregnancy or positive -HCG within 7 days of procedure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Renal sympathetic denervation
Catheter-based Renal Sympathetic Denervation Ablation Arm
|
Other Names:
|
|
Placebo Comparator: VT ablation alone
No further therapy in addition to VT ablation
|
Placebo arm will receive standard VT ablation using current techniques
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Freedom From First Event Requiring ICD Therapy
Time Frame: 24 months
|
Probability of freedom from first event requiring ICD therapy at 12 months and at 24 months
|
24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Appropriate ICD Shocks for Ventricular Arrhythmia
Time Frame: at 24 months
|
An Appropriate ICD therapy is defined as anti-tachycardia pacing (ATP) or shock therapy for ventricular tachycardia or fibrillation.
|
at 24 months
|
|
Number of Inappropriate ICD Therapy
Time Frame: at 24 months
|
Number of inappropriate ICD therapy including both appropriate and inappropriate shocks
|
at 24 months
|
|
All ICD Therapies (Appropriate + Inappropriate)
Time Frame: 24 months
|
cumulative ICD therapies including both appropriate and inappropriate shocks
|
24 months
|
|
Number of Participants With Mortality, ICD Storm and Incessant VT
Time Frame: 24 months
|
Number of Participants with a composite of Mortality, ICD storm, and Incessant VT
|
24 months
|
|
Number of Participants With Hospitalizations for Cardiovascular Causes
Time Frame: 24 months
|
24 months
|
|
|
Number of Episodes of Total VT Burden
Time Frame: at 24 months
|
Total VT burden (Number of episodes)
|
at 24 months
|
|
Number of Participants With All-Cause Mortality
Time Frame: 24 months
|
24 months
|
|
|
Number of Participants With Occurrences of ICD Storm
Time Frame: 24 months
|
The occurrence of ICD storm, defined as ≥3 appropriate shock therapies within 24 hours.
|
24 months
|
|
Change in Brain Natriuretic Peptide (BNP)
Time Frame: at baseline and at 12 months
|
Differences in blood hormone measurements as measured by BNP as compared on 12 months to baseline.
|
at baseline and at 12 months
|
|
Differences in BUN/Creatinine Measurements
Time Frame: baseline and 12 months
|
Differences in BUN/creatinine measurements compared at 12 months to baseline.
|
baseline and 12 months
|
|
Change in LV Size
Time Frame: baseline and 12 months
|
LV size measured by trans-thoracic echocardiography, as compared at 12 months to baseline
|
baseline and 12 months
|
|
Number of Procedure-related Adverse Events
Time Frame: 24 months
|
Procedure related adverse events including, but not limited to hematomas, pseudoaneurysms, renal artery stenosis, renal impairment, thromboembolic events, stroke, pericardial bleeding including tamponade and myocardial infarction.
|
24 months
|
|
Changes in Mean Arterial Pressure
Time Frame: baseline and 24 months
|
Change in mean arterial pressure
|
baseline and 24 months
|
|
Number of Participants With Orthostatic Hypertension
Time Frame: 24 months
|
Number of participants with other individual complication rates specifically orthostatic hypertension
|
24 months
|
|
Number of Participants With Other Complications
Time Frame: at 24 months
|
Other individual complication rates including, but not limited to MI and death
|
at 24 months
|
|
Number of Occurrences of Major Complication Rate
Time Frame: 30 days
|
30-day Major Complication Rate defined as death, stroke, MI or any other serious adverse events related to the treatment or procedure within the first 30 days or through hospital discharge (whichever is longer)
|
30 days
|
|
Procedure Time
Time Frame: during procedure
|
Renal Denervation Procedure time
|
during procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GCO 13-1462
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.